跳至主要内容
临床试验/NCT01492400
NCT01492400已完成2 期

Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema

Allergan0 个研究点目标入组 363 人开始时间: 2012年3月9日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
Allergan
入组人数
363
主要终点
Average Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye

研究概览

简要总结

This study will compare the safety and efficacy of the 700 ug dexamethasone intravitreal implant with ranibizumab 0.5 mg intravitreal injections in patients with diabetic macular edema (DME).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of type 1 or 2 diabetes mellitus
  • Diagnosis of macular edema
  • Visual acuity between 20/200 to 20/40

排除标准

  • Eye surgery to the study eye within 3 months
  • Use of Ozurdex® within 9 months
  • Any active ocular inflammation and infection
  • Diagnosis of glaucoma
  • Use of anti-VEGF treatment (e.g., Lucentis®) within 3 months in the eye or systemic use (e.g., Avastin®) within 6 months

研究组 & 干预措施

dexamethasone Intravitreal Implant

Experimental

Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10.

干预措施: dexamethasone Intravitreal Implant (Drug)

ranibizumab

Active Comparator

Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression.

干预措施: ranibizumab (Drug)

结局指标

主要结局

Average Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye

时间窗: Baseline, 12 Months

BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The average BCVA is calculated across study visits for each patient. A positive number change from baseline indicates an improvement and a negative number change from baseline indicates a worsening.

次要结局

  • Change From Baseline in Foveal Thickness Measured by Optical Coherence Tomography (OCT) in the Study Eye(Baseline, Month 12)
  • Change From Baseline in Total Area of Macular Leakage in the Study Eye Measured on Fluorescein Angiography (FA)(Baseline, Month 12)

研究者

发起方
Allergan
申办方类型
Industry
责任方
Sponsor

相似试验